Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05635708
Registration number
NCT05635708
Ethics application status
Date submitted
23/11/2022
Date registered
2/12/2022
Date last updated
22/06/2025
Titles & IDs
Public title
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
Query!
Scientific title
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
Query!
Secondary ID [1]
0
0
CTR20230892
Query!
Secondary ID [2]
0
0
BGB-LC-201
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non-small Cell Lung Cancer
0
0
Query!
Metastatic Non-small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Tislelizumab
Treatment: Drugs - BGB-A445
Treatment: Drugs - LBL-007
Treatment: Drugs - Carboplatin
Treatment: Drugs - Cisplatin
Treatment: Drugs - pemetrexed
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Nab paclitaxel
Treatment: Drugs - BGB-15025
Experimental: Sub-study 1: Arm 1A - Tislelizumab + BGB-A445
Experimental: Sub-study 1: Arm 2A - Tislelizumab + LBL-007
Experimental: Sub-study 1: Arm 3A - Tislelizumab + BGB-15025
Active comparator: Sub-study 1: Reference Arm Tislelizumab alone - Tislelizumab alone
Experimental: Sub-study 2: Arm 1B - Tislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-A445
Experimental: Sub-study 2: Arm 2B - Tislelizumab + investigator's choice of histology-appropriate chemotherapy + LBL-007
Experimental: Sub-study 2: Arm 3B - Tislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-15025
Active comparator: Sub-study 2: Reference Arm - Tislelizumab + investigator's choice of histology-appropriate chemotherapy
Treatment: Drugs: Tislelizumab
Administered by intravenous infusion
Treatment: Drugs: BGB-A445
Administered by intravenous infusion
Treatment: Drugs: LBL-007
Administered by intravenous infusion
Treatment: Drugs: Carboplatin
Investigator's choice; administered by intravenous infusion
Treatment: Drugs: Cisplatin
Investigator's choice; administered by intravenous infusion
Treatment: Drugs: pemetrexed
Investigator's choice; administered by intravenous infusion
Treatment: Drugs: Paclitaxel
Investigator's choice; administered by intravenous infusion
Treatment: Drugs: Nab paclitaxel
Investigator's choice; administered by intravenous infusion
Treatment: Drugs: BGB-15025
Administered Orally
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Confirmed overall response rate (ORR)
Query!
Assessment method [1]
0
0
ORR is defined as the percentage of participants with partial or complete response, as assessed by the investigator using the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1
Query!
Timepoint [1]
0
0
Up to 6 months
Query!
Secondary outcome [1]
0
0
Progression-free survival (PFS)
Query!
Assessment method [1]
0
0
PFS is defined as the time from date of randomization, or the first dose for safety lead-in participants , until first documentation of progression or death, whichever comes first, as assessed by the investigator using RECIST v1.
Query!
Timepoint [1]
0
0
Up to 1 year
Query!
Secondary outcome [2]
0
0
Duration of Response (DOR)
Query!
Assessment method [2]
0
0
DOR is defined as the time from the first determination of a confirmed response per RECIST v1.1 until the first documentation of progression or death, whichever comes first as assessed by the investigator
Query!
Timepoint [2]
0
0
Up to 1 year
Query!
Secondary outcome [3]
0
0
Clinical Benefit Rate (CBR)
Query!
Assessment method [3]
0
0
CBR is defined as the percentage of participants with a best overall response of a complete response, partial response, or durable stable disease, as assessed by the investigator using RECIST v1.1
Query!
Timepoint [3]
0
0
Up to 6 months
Query!
Secondary outcome [4]
0
0
Disease Control Rate (DCR)
Query!
Assessment method [4]
0
0
DCR is defined as the percentage of participants with a best overall response of complete response, partial response, or stable disease, as assessed by the investigator using RECIST v1.1
Query!
Timepoint [4]
0
0
Up to 6 months
Query!
Secondary outcome [5]
0
0
Number of participants with adverse events (AEs)
Query!
Assessment method [5]
0
0
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory values, vital signs, physical examination findings, and electrocardiogram results.
Query!
Timepoint [5]
0
0
From the first dose of study drug(s) to 90 days after initiation of new anticancer therapy, death, withdrawal of consent, or loss to follow-up, whichever occurs first, up to approximately 2 years
Query!
Eligibility
Key inclusion criteria
Key
1. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), including nonsquamous or squamous subtypes, that is either locally advanced or recurrent and not eligible for curative surgery and/or definitive chemoradiotherapy, or metastatic NSCLC.
2. No prior systemic therapy administered as the primary treatment for metastatic NSCLC. Prior adjuvant or neoadjuvant chemotherapy, definitive chemoradiation, or adjuvant radiotherapy for locally advanced disease is permitted, provided the last dose of chemotherapy and/or radiotherapy occurred at least 6 months prior to randomization/enrollment.
3. Tumor programmed death-ligand 1 (PD-L1) expression must be evaluable, as determined by a local or central laboratory using archival tumor tissue or a fresh biopsy. Participants with unknown PD-L1 expression are not eligible.
4. At least one measurable lesion, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Diagnosis of mixed small cell lung cancer.
2. Known genomic alterations for which effective targeted therapies are available according to local standard of care, including but not limited to:
* Epidermal growth factor receptor (EGFR) mutations
* Anaplastic lymphoma kinase (ALK) rearrangements
* B-Raf proto-oncogene (BRAF) mutations
* Rearranged during transfection (RET) fusions
* c-ros oncogene 1 (ROS1) rearrangements
3. Participants with nonsquamous NSCLC and unknown EGFR mutation status must undergo local testing. Those found to have EGFR-sensitizing mutations will be excluded.
4. Prior treatment with immune-based therapies that target immune checkpoint pathways, including:
* PD-1 (programmed cell death protein 1) inhibitors
* PD-L1 (programmed death-ligand 1) inhibitors
* PD-L2 (programmed death-ligand 2) inhibitors
* TIGIT (T cell immunoreceptor with Ig and ITIM domains) inhibitors
* LAG-3 (lymphocyte activation gene 3) inhibitors
5. Participants previously treated with these agents in a neoadjuvant, adjuvant, or consolidation setting may be eligible if a treatment-free interval of at least 6 months has elapsed since the last dose and radiologic evidence of recurrence is present.
6. Use of Chinese herbal medicines or Chinese patent medicines intended for cancer control within 14 days prior to randomization/enrollment.
7. Presence of active leptomeningeal disease, untreated or uncontrolled brain metastases, or active autoimmune disease.
Note: Additional protocol-defined and sub-study-specific criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/03/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/10/2025
Query!
Actual
Query!
Sample size
Target
400
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,WA
Query!
Recruitment hospital [1]
0
0
Blacktown Cancer and Haematology Centre - Blacktown
Query!
Recruitment hospital [2]
0
0
Chris Obrien Lifehouse - Camperdown
Query!
Recruitment hospital [3]
0
0
Northern Beaches Hospital - Frenchs Forest
Query!
Recruitment hospital [4]
0
0
Port Macquarie Base Hospital - Port Macquarie
Query!
Recruitment hospital [5]
0
0
One Clinical Research - Nedlands
Query!
Recruitment hospital [6]
0
0
St John of God Health Care - Subiaco
Query!
Recruitment postcode(s) [1]
0
0
2148 - Blacktown
Query!
Recruitment postcode(s) [2]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [3]
0
0
2086 - Frenchs Forest
Query!
Recruitment postcode(s) [4]
0
0
2444 - Port Macquarie
Query!
Recruitment postcode(s) [5]
0
0
6009 - Nedlands
Query!
Recruitment postcode(s) [6]
0
0
6008 - Subiaco
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Massachusetts
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
New York
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Oregon
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Texas
Query!
Country [6]
0
0
Brazil
Query!
State/province [6]
0
0
Barretos
Query!
Country [7]
0
0
Brazil
Query!
State/province [7]
0
0
Londrina
Query!
Country [8]
0
0
Brazil
Query!
State/province [8]
0
0
Porto Alegre
Query!
Country [9]
0
0
Brazil
Query!
State/province [9]
0
0
Sao Jose Do Rio Preto
Query!
Country [10]
0
0
Brazil
Query!
State/province [10]
0
0
Sao Paulo
Query!
Country [11]
0
0
Canada
Query!
State/province [11]
0
0
Alberta
Query!
Country [12]
0
0
China
Query!
State/province [12]
0
0
Anhui
Query!
Country [13]
0
0
China
Query!
State/province [13]
0
0
Beijing
Query!
Country [14]
0
0
China
Query!
State/province [14]
0
0
Fujian
Query!
Country [15]
0
0
China
Query!
State/province [15]
0
0
Hebei
Query!
Country [16]
0
0
China
Query!
State/province [16]
0
0
Heilongjiang
Query!
Country [17]
0
0
China
Query!
State/province [17]
0
0
Henan
Query!
Country [18]
0
0
China
Query!
State/province [18]
0
0
Hubei
Query!
Country [19]
0
0
China
Query!
State/province [19]
0
0
Jiangsu
Query!
Country [20]
0
0
China
Query!
State/province [20]
0
0
Jiangxi
Query!
Country [21]
0
0
China
Query!
State/province [21]
0
0
Shandong
Query!
Country [22]
0
0
China
Query!
State/province [22]
0
0
Shanghai
Query!
Country [23]
0
0
China
Query!
State/province [23]
0
0
Shanxi
Query!
Country [24]
0
0
China
Query!
State/province [24]
0
0
Tianjin
Query!
Country [25]
0
0
China
Query!
State/province [25]
0
0
Zhejiang
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Paris
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
SaintHerblain
Query!
Country [28]
0
0
Georgia
Query!
State/province [28]
0
0
Tbilisi
Query!
Country [29]
0
0
Italy
Query!
State/province [29]
0
0
Roma
Query!
Country [30]
0
0
Italy
Query!
State/province [30]
0
0
Verona
Query!
Country [31]
0
0
Korea, Republic of
Query!
State/province [31]
0
0
Chungcheongbukdo
Query!
Country [32]
0
0
Korea, Republic of
Query!
State/province [32]
0
0
Gyeonggi-do
Query!
Country [33]
0
0
Korea, Republic of
Query!
State/province [33]
0
0
Seoul Teugbyeolsi
Query!
Country [34]
0
0
Malaysia
Query!
State/province [34]
0
0
Georgetown
Query!
Country [35]
0
0
Malaysia
Query!
State/province [35]
0
0
Johor Bahru
Query!
Country [36]
0
0
Malaysia
Query!
State/province [36]
0
0
Kuantan
Query!
Country [37]
0
0
Malaysia
Query!
State/province [37]
0
0
Kuching
Query!
Country [38]
0
0
Malaysia
Query!
State/province [38]
0
0
Petaling Jaya
Query!
Country [39]
0
0
Moldova, Republic of
Query!
State/province [39]
0
0
Chisinau
Query!
Country [40]
0
0
Romania
Query!
State/province [40]
0
0
Bucureti
Query!
Country [41]
0
0
Romania
Query!
State/province [41]
0
0
ClujNapoca
Query!
Country [42]
0
0
Singapore
Query!
State/province [42]
0
0
Singapore
Query!
Country [43]
0
0
Spain
Query!
State/province [43]
0
0
Barcelona
Query!
Country [44]
0
0
Spain
Query!
State/province [44]
0
0
Madrid
Query!
Country [45]
0
0
Spain
Query!
State/province [45]
0
0
Sevilla
Query!
Country [46]
0
0
Thailand
Query!
State/province [46]
0
0
Hat Yai
Query!
Country [47]
0
0
Thailand
Query!
State/province [47]
0
0
Muang
Query!
Country [48]
0
0
Thailand
Query!
State/province [48]
0
0
Ongkharak
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
BeiGene
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (= 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (\< 50%).
Query!
Trial website
https://clinicaltrials.gov/study/NCT05635708
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Study Director
Query!
Address
0
0
BeiGene
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
BeiGene
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+1-877-828-5568
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
See plan description
Query!
Available to whom?
See plan description
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://beigene.com/science/clinical-trials/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05635708
Download to PDF